Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VERV Verve Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VERV
Price (delayed)
$5.29
Market cap
$471.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.11
Enterprise value
$428.36M
Highlights
VERV's gross profit has soared by 84% since the previous quarter
Verve Therapeutics's revenue has soared by 84% from the previous quarter
The quick ratio has dropped by 51% year-on-year and by 22% since the previous quarter
Verve Therapeutics's equity has decreased by 19% YoY and by 4% from the previous quarter
Key stats
What are the main financial stats of VERV
Market
Valuations
Earnings
Shares outstanding
89.14M
Market cap
$471.57M
Enterprise value
$428.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.99
Price to sales (P/S)
7.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.19
Revenue
$59.61M
Gross profit
$59.61M
Operating income
-$208.45M
Net income
-$181.01M
EBIT
-$180.68M
EBITDA
-$166.54M
Free cash flow
-$146.98M
Per share
Balance sheet
Liquidity
EPS
-$2.11
EPS diluted
-$2.11
Free cash flow per share
-$1.66
Book value per share
$5.33
Revenue per share
$0.67
TBVPS
$6.92
Total assets
$614.16M
Total liabilities
$140.65M
Debt
$58.12M
Equity
$473.51M
Working capital
$459.67M
Debt to equity
0.12
Current ratio
9.84
Quick ratio
9.68
Net debt/EBITDA
0.26
Margins
Efficiency
Dividend
EBITDA margin
-279.4%
Gross margin
100%
Net margin
-303.6%
Operating margin
-349.7%
Return on assets
-27.6%
Return on equity
-35.8%
Return on invested capital
-34.1%
Return on capital employed
-32.1%
Return on sales
-303.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VERV stock price
How has the Verve Therapeutics stock price performed over time
Intraday
9.3%
1 week
24.76%
1 month
1.93%
1 year
0%
YTD
-6.21%
QTD
15.75%
Financial performance
How have Verve Therapeutics's revenue and profit performed over time
Revenue
$59.61M
Gross profit
$59.61M
Operating income
-$208.45M
Net income
-$181.01M
Gross margin
100%
Net margin
-303.6%
VERV's gross profit has soared by 84% since the previous quarter
Verve Therapeutics's revenue has soared by 84% from the previous quarter
The operating margin has soared by 75% YoY and by 51% from the previous quarter
VERV's net margin has surged by 75% year-on-year and by 51% since the previous quarter
Price vs fundamentals
How does VERV's price correlate with its fundamentals
Growth
What is Verve Therapeutics's growth rate over time
Valuation
What is Verve Therapeutics stock price valuation
P/E
N/A
P/B
0.99
P/S
7.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.19
Verve Therapeutics's EPS has increased by 26% YoY and by 10% QoQ
The P/B is 62% below the 5-year quarterly average of 2.6 but 24% above the last 4 quarters average of 0.8
Verve Therapeutics's equity has decreased by 19% YoY and by 4% from the previous quarter
Verve Therapeutics's revenue has soared by 84% from the previous quarter
The price to sales (P/S) is 46% less than the last 4 quarters average of 14.6
Efficiency
How efficient is Verve Therapeutics business performance
Verve Therapeutics's return on sales has surged by 75% YoY and by 51% QoQ
The ROA has grown by 6% YoY and by 4.8% from the previous quarter
VERV's return on invested capital is up by 4.7% since the previous quarter
VERV's ROE is up by 4% QoQ and by 4% YoY
Dividends
What is VERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VERV.
Financial health
How did Verve Therapeutics financials performed over time
The quick ratio has dropped by 51% year-on-year and by 22% since the previous quarter
The current ratio has dropped by 50% year-on-year and by 22% since the previous quarter
VERV's debt is 88% smaller than its equity
Verve Therapeutics's equity has decreased by 19% YoY and by 4% from the previous quarter
VERV's debt to equity is up by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.